Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score

AIDS

Volumn 21, Issue 14, 2007, Pages 1867-1875

  Mocroft, Amanda ^a   Ledergerber, Bruno ^b   Zilmer, Kai ^e   Kirk, Ole ^f   Hirschel, Bernard ^c   Viard, Jean Paul ^g   Reiss, Peter ^h   Francioli, Patrick ^d   Lazzarin, Adriano ⁱ   Machala, Ladislav ^j   Phillips, Andrew N ^a   Lundgren, Jens D ^f  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

more..

Author keywords

Combination antiretroviral therapy; Disease progression; EuroSIDA; Risk assessment

Indexed keywords

ABACAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANEMIA; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; VIRAL LOAD;

EID: 34548250117     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328270b877     Document Type: Article

References (36)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-1730.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Br Med J 1997; 315:1194-1199.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
4. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure. A randomised trial. JAMA 2002; 288:169-180.
5. Gullick RM, Ribaudo HJ, Shikurma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
6. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
7. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999; 353:863-868.
8. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ,O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
9. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, d'Arminio Monforte A, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. J Infect Dis 2002; 185:178-187.
10. Cozzi Lepri A, Sabin CA, Phillips AN, Lee CA, Pezzotti P, Rezza G, et al. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. Int J Epidemiol 1998; 121:369-376.
11. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of intiial virological failure of combination antiretroviral therapy. Arch Intern Med 2006; 166:521-528.
12. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
13. Center for Disease Control. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
14. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13:941-950.
15. US National Institutes of Health. Guidelines for the use of antiretroviral agents in HIV-1 infected adults andadolescents. Bethesda, MD: National Institutes of Health. http://AIDSinfo.nih.gov. Accessed 1 March 2007.
16. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P, and the Swiss HIV Cohort Study. Clinical epidemiology and research on HIV infection in Switzerland: The Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000; 130:1493-1500.
17. Anastos K, Shi Q, French AL, Levine A, Greenblatt RM, Williams C, et al. Total lymphocyte count, hemoglobin, and delayed type hypersensitivity as predictors of death and AIDS illness in HIV-1 infected women receiving highly active antiretroviral therapy. J AIDS 2004; 35:383-392.
18. CASCADE collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58.
19. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J AIDS 1998; 18:80-85.
20. Rockstroh JJ, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
21. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
22. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes of death in HIV infection: The key determinant to define the clinical response to anti-HIV therapy. AIDS 2004; 18:2233-2237.
23. Chene G, Easterbrook PJ, Jaczczak E, Yu LM, Pocock SJ, Gazzard BJ, et al. Long term survival in patients with advanced immunodeficiency. AIDS 1997; 11:209-216.
24. Goebel FD. Immune reconstitution inflammatory syndrome (IRIS): another new disease entity following treatment initiation of HIV infection. Infection 2005; 33:43-45.
25. Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected persons in HIV infected patients on highly active antiretroviral therapy. AIDS 1999; 13:525-526.
26. Telenti A, Munoz M, Bleiber G, Ledergerber B, Kauffman D. Heterogeneity in the response to antiretroviral therapy. AIDS Rev 1999; 1:147-155.
27. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-2257.
28. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
29. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study. Lancet 2000; 356:1800-1805.
30. Anastos K, Barron Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, et al. The prognostic importance of changes in CD4R cell count and HIV RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-264.
31. Kjaer J, Ledergerber B, for the HIV Cohort Collaborations. Proposal for harmonisation of data exchange. Antivir Ther 2004; 9:631-633.
32. Justice AC, Covinsky KE, Berlin JA. Assessing the generalisability of prognostic information. Ann Intern Med 1999; 130:515-524.
33. Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, et al. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical trials 2006; 3:119-132.
34. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
35. D'Arminio Monforte A, Cozzi-Lepri A, Phillips A, De Luca A, Murri R, Mussini C, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice. Results from the Italian Cohort of Antiretroviral-Naive patients. J AIDS 2005; 38:407-416.
36. Holkmann-Olsen C, Mocroft A, Vella S, Blaxhult A, Clumeck N, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8:96-104.